|Bid||59.56 x 500|
|Ask||60.39 x 100|
|Day's Range||59.58 - 60.32|
|52 Week Range||57.80 - 80.02|
|PE Ratio (TTM)||10.85|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
New Research Reports for Oracle, Chubb, AstraZeneca & Others
A possible entry into mail-order pharmacy could significantly disrupt this massive market.
Last week, short-sell Jim Chanos made his bear case for Mallinckrodt (MNK) and Express Scripts (ESRX) at the SALT Conference. Mallinckrodt released a statement on Friday taking issue with numerous components of Chanos' argument, including the percentage of its profit that comes from Acthar: Mallinckrodt does not publicly disclose profitability of the individual products in its diversified portfolio. Inflated assertions regarding H.P. Acthar® Gel’s contribution to the company’s overall profitability are incorrect.